ArticleBMC cardiovascular disorders2026
Clinical efficacy of transcatheter aortic valve replacement in patients with rheumatic aortic stenosis.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The "Cairo Accord"- towards the eradication of RHD: revisited (2026).Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) is contraindicated for rheumatic aortic stenosis (RAS). Evidence on the efficacy and safety of TAVR is scarce despite several cases of RAS recorded in China. This study aimed to evaluate the efficacy of TAVR in patients with RAS.
methodsA total of 359 patients were enrolled and divided into the RAS ( n = 71) and non-RAS ( n = 288) groups according to the World Heart Federation guidelines for rheumatic heart disease combined with computed tomography imaging. Propensity score matching was performed to ensure comparability between groups. A self-expanding valve was used in all the patients. Primary endpoints included technical success, device success, and 1-year composite outcomes. Short-term complications and anatomical differences were analysed.
resultsPatients with RAS had higher N-terminal pro-B-type natriuretic peptide levels and Society of Thoracic Surgeons scores, higher atrial fibrillation rates, and worse cardiac metrics (enlargement, valve regurgitation, and lower estimated glomerular filtration rates). The patients in the RAS group had fewer bicuspid valves, less calcification, more elliptical annuli, and larger left ventricular outflow tract/annulus area ratios. The RAS group had a higher prosthesis positioning and oversizing rate. Technical success, device success, and early safety rates were similar between groups. However, the RAS group had a higher pacemaker implantation and transcatheter heart valve displacement (THVD) risk, yet demonstrated superior 1-year outcomes.
conclusionsTAVR may be safe and effective for the treatment of RAS. The anatomical characteristics of patients with RAS increased the risk of THVD and pacemaker implantation. A high-release strategy and appropriate oversizing could partially alleviate the risk of THVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.